Author
David Chen, MD, PhD
Board-certified endocrinologist
Dr. David Chen is a board-certified endocrinologist specializing in obesity medicine, with 15 years of clinical experience. He has treated over 800 patients with pharmaceutical weight-loss interventions including semaglutide, tirzepatide, and retatrutide.
He completed his endocrinology fellowship at Massachusetts General Hospital and maintains an active clinical practice at Metropolitan Endocrinology Associates, where he also serves as an investigator on clinical trials of GLP-1 receptor agonists and other metabolic compounds.
Dr. Chen has published research on metabolic adaptation after weight loss and serves on the medical advisory board of the Obesity Medicine Association. He advocates for evidence-based, realistic approaches to obesity treatment that acknowledge both the power and the limitations of pharmaceutical interventions.
Articles by David Chen
- Understanding Retatrutide's Half-Life
A research-focused look at retatrutide's pharmacokinetics, why its ~6-day half-life shapes once-weekly dosing schedules, and what that means for protocol design.
- Bacteriostatic Water: What It Does and Why It Matters
A short explainer on benzyl alcohol, why reconstitution diluent isn't interchangeable, and the storage trade-offs that come with each option.
- GLP-1, GIP, and Glucagon: What a Triple Agonist Profile Actually Means
A plain-language walkthrough of why retatrutide is a different class of molecule from semaglutide, and what each receptor contributes in research models.
- How We Vet a New Peptide Manufacturer
A short note on the steps we run before any new supplier's product reaches our shelves, and why the cheapest source is almost never the right one.